Key points
In our guide to SIBO berberine appears in a single line — as the intervention that topped a network meta-analysis; here, in detail, is what studies in people showed.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Uncomplicated SIBO | a possible agent for eradication — clearing the bacterial overgrowth | 2025 network meta-analysis (30 RCTs, 1552 participants, 12 interventions): berberine had the highest SUCRA value — first place on ranking probability (the data on it come from one trial of 46 people); the authors call it a potentially favourable option for SIBO eradication (PMID 41394885) |
| Type 2 diabetes: blood glucose | berberine alone lowers fasting and 2-hour glucose | 2024 meta-analysis (50 trials, 4150 participants): fasting glucose −0.59 mmol/L (−11 mg/dL), 2-hour glucose −1.57 mmol/L (−28 mg/dL) (PMID 39640489) |
| Triglycerides | berberine alone lowers triglycerides | −0.35 mmol/L (−31 mg/dL) in the same meta-analysis |
| Alongside glucose-lowering drugs | may assist prescribed treatment | in the same meta-analysis fasting glucose −0.99 mmol/L (−18 mg/dL), 2-hour glucose −1.07 mmol/L (−19 mg/dL), HbA1c −0.69% |
How it helps
First place in the SIBO ranking
The source is a 2025 network meta-analysis (PMID 41394885): 30 randomised trials, 1552 participants, 12 different interventions, with the protocol registered in PROSPERO. It gathers trials that never overlapped with each other into a single network and arranges the interventions into a ranking.
Berberine received the highest SUCRA value in that ranking — 82.5%. The data on it in this network come from one trial of 46 people, a direct comparison with rifaximin: berberine was numerically higher, and the difference was not statistically significant. The authors write that this positions it as a potentially favourable option for SIBO eradication.
What SUCRA is. It is the probability of ranking above the others within a network of comparisons — a numerical measure of «most likely nearer the top». It is computed from indirect links: if A was compared with placebo and B was compared with placebo, the network estimates A against B even though nobody ever compared them.
The comparison with rifaximin
The head-to-head is already under way. The BRIEF-SIBO trial (PMID 36873985): 180 patients, berberine against rifaximin, 400 mg twice daily for two weeks, six weeks of follow-up, primary outcome a negative breath test. The stated hypothesis is that berberine is not inferior to rifaximin. An interim analysis in 46 people supported it: berberine was not inferior to rifaximin (conference abstract, 2024). Final results are awaited.
Metabolism
The second reason to be interested is metabolism, and the evidence base there is considerably larger. A 2024 meta-analysis pooled 50 trials and 4150 participants (PMID 39640489); the results are in the «Key points» table.
The detailed comparison with metformin is covered separately — berberine or metformin, on mechanisms, doses and how the side-effect profiles differ.
How to take it
The dose studied in SIBO is 800 mg of berberine a day: in the BRIEF-SIBO trial that is 400 mg twice daily for two weeks. In metabolic research the usual range is 0.9–1.5 g a day for one to three months.
Now look at what a supplement actually contains. Very often it is not berberine but barberry extract standardised to 2% berberine. Which means a «500 mg» capsule holds roughly 10 mg of the active compound. And the label usually reads «up to 2%» — a ceiling rather than a promise: the real figure may be lower.
Do the arithmetic. To reach the studied 800 mg a day from such an extract you would need about eighty capsules daily. This is not a complaint about the manufacturer — barberry extract is honestly labelled as an extract. It is a reason to read the composition to the end.
The practical rule in one line: look at the milligrams of berberine, not the milligrams of extract. If the package gives only the weight of the extract and the percentage of standardisation, multiply them.
Who should see a doctor first
Berberine is sold as a supplement, but it has at least three properties that in a pharmacy medicine would land in the contraindications section.
1. It raises the levels of other drugs
The weightiest evidence is not laboratory work but people. A randomised trial in renal transplant recipients (PMID 16133554): 52 patients took cyclosporine together with berberine, 52 without it, for three months.
| Cyclosporine measure | Change with berberine |
|---|---|
| Area under the curve (AUC) | +34.5% |
| Trough concentration | +88.3% |
| Half-life | +2.7 hours |
| Clearance | −40.4% |
For a drug with a narrow therapeutic window that is a great deal. In animal work (PMID 19370549) berberine likewise increased digoxin absorption — the area under the curve reached 170% of control, and only with oral dosing, meaning the effect is intestinal.
Hence the rule: if you take immunosuppressants, cardiac glycosides, anticoagulants or anticonvulsants, berberine is discussed with a physician, not added alongside them.
2. Pregnancy, breastfeeding and newborns
Who must not take it: pregnancy, breastfeeding, newborns.
Berberine displaces bilirubin from its binding to albumin. In a laboratory study (PMID 8513024) it proved, on a molar basis, about tenfold more potent than phenylbutazone — a known displacer of bilirubin.
For an adult that carries little weight. For a newborn it is a risk of free bilirubin reaching the brain. The US National Institutes of Health lactation database puts it plainly: most sources recommend avoiding newborn exposure to berberine, including through breast milk — and honestly adds that the extent of transfer from mother to infant is unknown.
In plain words. Unknown does not mean safe. It means the proposed test subject is the baby.
3. The ordinary side effects
A 2023 umbrella review pooling eleven meta-analyses (PMID 36999891) names constipation and diarrhoea as the common gastrointestinal effects. Overall it rates berberine as a safe ingredient.
Bottom line
Berberine is a compound with real pharmacology: in uncomplicated SIBO it topped a network meta-analysis ranking, a head-to-head comparison with rifaximin is already running, and in metabolism it slightly lowers glucose and triglycerides and may assist prescribed treatment. That is exactly why it deserves to be treated like a medicine: check the dose, check the interactions, check the contraindications.
And the thing worth taking away even if the rest is forgotten: with bloating, what decides the outcome is not the choice of agent but the order of steps — check first, then treat, and treat the person rather than the test.
Source: Berberine for SIBO: first in the ranking, with nothing yet to compare it against — universum.earth. Dr. Pereligyn.
